Estimating the economic impact of acute coronary syndrome in New Zealand over time (ANZACS-QI 64): a national registry-based cost burden study.

Peter LeeA J KerrYannan JiangElla ZomerDanny Liew

Published in: BMJ open (2022)

The economic cost of hospitalisations for ACS in NZ decreased considerably over time. Further studies are warranted to explore the association between reductions in ACS cost burden and changes in the management of ACS.

Keyphrases

acute coronary syndrome
percutaneous coronary intervention
antiplatelet therapy
risk factors
case control
life cycle